PATIENTS, MATERIALS, AND METHODS

Setting.
Our hospital is a 1750-bed, tertiary care, referral, general teaching institution. The heart surgery ICU of our hospital is a 14-bed postsurgery unit for all adult patients who have undergone a major cardiac surgical procedure.
Study of the outbreak of infection. During the period of 15-30 April 2003, we detected 3 patients with S. cerevisiae fungemia in our ICU. The medical records for 41 patients who had been in the unit during the second half of April 2003 were reviewed, in accordance with an established protocol, for epidemiological data, presence of Clostridium difficile-associated diarrhea, and use of Saccharomyces boulardii probiotic. Feces and pharynx surveillance cultures for the 14 patients in the ICU were also performed when the outbreak of infection was detected to test for S. cerevisiae carriage. Capsules of the probiotic were obtained for culture. NOTE. ALL, acute lymphocytic leukemia; AmB, amphotericin B; AML, acute myelogenous leukemia; ARDS, acute respiratory distress syndrome; BMT, bone marrow transplantation; CDAD, Clostridium difficileassociated diarrhea; CML, chronic myelogenous leukemia; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; DM, diabetes mellitus; E, enteral; 5FC, 5-fluorocytosine; Flu, fluconazole; GVHD, graft-versus-host disease; IDA, injection drug abuser; Keto, keotconazole; L-AmB, liposomal amphotericin B; MAID, Mycobacterium avium intracellulare disease; Mico, miconazole; NA, not applicable; NR, not reported; NRe, nonrelated; P, parenteral; PR, present report; PVE, prosthetic valve endocarditis; RF, renal failure; Sb, Saccharomyces boulardii.
a Seven months old. b Eight months old. c One month old.
Identification of fungal isolates and susceptibility testing. One isolate from each patient with S. cerevisiae fungemia and the strain recovered from the probiotic capsules (the 4 study strains) were sent to the Mycology Reference Laboratory of the National Center for Microbiology of Spain (Madrid) for definitive identification and susceptibility testing. The isolates were identified by routine morphological and physiological tests [5, 6] .
Susceptibility testing was conducted strictly on the basis of recommendations proposed by the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing for testing of fermentative yeasts (AFST-EUCAST discussion document 7.1) [7] . Candida parapsilosis ATCC22019 and Candida krusei ATCC6258 were used as quality-control strains.
The antifungal agents used in the study were amphotericin B, flucytosine, fluconazole, itraconazole, and voriconazole. These agents were dissolved in 100% dimethylsulfoxide (Sigma Aldrich Quimica). The MICs were determined at 24 and 48 h. MICs were obtained by measuring the absorbance at 530 nm with an MRXII reader (Dynatech; Cultek). For amphotericin B, the MIC end points were defined as the lowest drug concentration exhibiting reduction in growth of у90%, compared with that of the control growth. For flucytosine and azole drugs, the MIC end point was defined as the lowest drug concentration exhibiting a reduction in growth of 50%. Molecular typing studies. Typing studies were performed on the basis of previously described procedures [8, 9] . The PCR fingerprinting procedure, which included 3 different primers, was used for molecular typing. The phage M13 core sequence (5 -GAGGGTGGCGGTTCT-3 ) and primers that targeted microsatellite sequences (GTG) 5 and (GACA) 4 were used to amplify the DNA of the different strains. Amplification reactions were done in accordance with methods described in the literature [8, 9] . Amplifications were performed in a thermal cycler (GenAmp PCR System 2700; Applied Biosystems). Each amplification was repeated at least twice to verify the presence or absence of the scored bands. The amplified products were electrophoresed through 1.3% agarose gels (Pronadisa) and were stained with ethidium bromide (Sigma Aldrich Química). After intensive washing with distilled water, gels were photographed under UV light. PCR profiles were analyzed visually and indexed by letters or numbers, and even a single mismatch led to a different letter or number code.
Eight other clinical isolates of S. cerevisiae were used as control organisms in molecular typing studies (i.e., control strains). All strains were recovered over a 7-year period (1997-2003) from 8 different Spanish hospitals. Each clinical isolate represented a single isolate from a patient. These control isolates were not geographically or temporally related.
Statistical analysis. Relationships between variables were evaluated using the x 2 statistic for categorical variables, Student's t test for normally distributed continuous variables, and the Mann-Whitney U test for nonparametric comparisons. All comparisons were considered to be statistically significant if the P value was р.05. Statistical analysis was performed using the SPSS software system (SPSS).
RESULTS
Case Reports
During the period of 15-30 April 2003, a total of 3 patients admitted to the major heart surgery ICU at our institution were found to have blood cultures positive for S. cerevisiae. These cases are described briefly below and in table 1. 
Colonization Surveillance
The results of feces and pharynx surveillance cultures for the 14 patients admitted to the unit when the outbreak of infection was recognized were negative for S. cerevisiae. No case of asymptomatic carriage was detected. 
Role of Ultralevura Probiotic
The 3 case patients were treated with a probiotic preparation before the fungemia (Ultralevura), whereas only 2 of 41 control patients admitted to the ICU during April 2003 had received it. Capsules of the probiotic Ultralevura contain lyophilized S. boulardii and were opened and dissolved in the ICU before nasogastric administration. No further cases have been detected since the use of Ultralevura was discontinued in the unit. The culture of the probiotic capsules showed heavy growth of a yeast (11,000,000 cfu/mL) similar to that recovered from the 3 fungemic patients. All of the yeasts were identified as S. cerevisiae.
Results of Susceptibility and Molecular Typing Tests
The susceptibility results for the 4 S. cerevisiae study strains (1 from each patient and 1 from the probiotic batch) are shown in figure 1A , and profiles obtained with (GACA) 4 are shown in figure 1B . The most discriminative primer was the M13 sequence. This primer yielded 7 different patterns of bands for control organisms. Five patterns (A-E) were observed when (GACA) 4 was used, and 4 profiles (a-d) were observed with the (GTG) 5 sequence. When the results obtained with the 3 primers were combined, the 8 control isolates were differentiated, and each control strain was classified into a different genomic type. The profiles were reproducible between different DNA preparations from the same strain, as well as between runs when samples were run a second time.
With regard to the 4 study strains that were isolated from the probiotic and from the 3 temporally related patients, the genomic patterns were identical regardless of the typing technique utilized. This could indicate that the 4 isolates were epidemiologically related.
Review of the Literature about All Cases of S. cerevisiae Fungemia
We searched the MEDLINE database for articles in English, French, or Spanish that were published since 1966 using the medical subject headings "cerevisiae" "boulardii," and "fungemia." We searched reference lists to identify additional reports of S. cerevisiae fungemia. Cases with insufficient clinical information were excluded from this analysis [48] [49] [50] [51] . Patients in whom the microorganism was not isolated from blood were also excluded [19, [52] [53] [54] [55] [56] .
We were able to identify 60 cases of S. cerevisiae fungemia, including the 3 reported by our group in this article. The most important characteristics of these patients are presented in table 1.
The mean age (‫ע‬SD) of the patients was years, 43 ‫ע‬ 26.8 and 7 patients were р1 year of age. Sex was reported for 57 patients, 31 (54.4%) of whom were male. Only 3 patients were healthy before the fungemia (2 patients with self-inflicted fungemia, who had infected themselves to escape from a prison camp, and 1 patient who ingested large quantities of brewer's yeast as a nutritional supplement). Overall, 28 (60%) of 47 patients whose data were reported were in the ICU when the fungemia was diagnosed, 35 (71%) of 49 were receiving enteral or parenteral nutrition, 55 (93%) of 59 had a central venous catheter in place, and 44 (88%) of 50 had received broadspectrum antimicrobials. Results of catheter-tip cultures were positive for 6 patients (10%).
The use of probiotics was reported for 26 (45.6%) of 57 patients, and 5 other patients (9%) with fungemia were in the vicinity of patients receiving this therapy. The fungemia was detected a median (‫ע‬SD) of days (range, 4-300 10 ‫ע‬ 62.3 days) after the administration of the probiotic. Typing procedures were used in 39% of cases, and the capsules were cultured in 13%.
We compared patients who had and who had not received previous Ultralevura probiotic therapy. The only significant differences between the 2 groups were that patients who received probiotic therapy were more commonly in the ICU (70% vs 41%;
), were more likely to have received parenteral or P p .05 enteral nutrition (84% vs 50%; ), and were less frequently P ! .01 treated with amphotericin B (32% vs 65%; 
60). All but 12 patients received antifungal therapy (20%).
The most common drugs received were fluconazole (16 patients) and amphotericin B (28 patients). The mortality rate was 28% (17 of 60 patients died). The only factor that increased the mortality rate was older age (mean age of patients who died and who survived, 60 years and 36 years, respectively; P ! ) .001
DISCUSSION
The extent of this review indicates that S. cerevisiae should be considered as a well-established cause of nosocomially acquired yeast infection, particularly in patients receiving prophylaxis or treatment with the probiotic Ultralevura (S. boulardii), which should be considered a risk factor for nosocomial bloodstream infection in patients with predisposing underlying conditions.
Saccharomyces is a ubiquitous ascomycetous yeast used by the food industry in the production of foodstuffs, wines, and beers. The identification of S. cerevisiae in the laboratory is not problematic and is usually based on the morphology of the yeast, its growth pattern, and biochemical studies (figure 1) [10] .
The genus Saccharomyces includes several species, the most well-known being S. cerevisiae. Genotyping techniques, such as rDNA sequencing and random amplified polymorphic DNA analysis, have been used to identify isolates of Saccharomyces to the species level [36, 44, 48, 57] . After some discussion [58] , S. boulardii, which is approved in many countries for the treatment or prevention of antibiotic-associated diarrhea, is now considered to be identical to a particular strain of S. cerevisiae [1, 46, 57] . This evidence is also supported by clinical studies such as ours, in which S. cerevisiae recovered from patients and S. boulardii strains isolated from probiotic preparations were proved to be genomically identical [3, 25, 30, 31, 36, 40, 45, 46] .
The incidence of S. cerevisiae fungemia is unknown, although population-based studies suggest that it is responsible for 0.1%-3.6% of all episodes of fungemia [45, 48, 49] . The first case was reported in 1970 in a patient with a prosthetic mitral valve [10] , and analysis of our review reveals an increase in the number of cases reported during the past decade (there were 4 cases reported during 1970-1980, 10 reported during 1981-1991, and 46 reported during 1992-2004) .
S. cerevisiae is a common colonizer of mucosal surfaces and part of the normal flora of the gastrointestinal tract, the respiratory tract, and the vagina [59] . Its presence in normally sterile fluids has been classically described in patients with rupture of the local barriers or with very high fungal loads. Portals of entry include translocation of ingested microorganisms from the enteral or oral mucosa [24, 25, 37, 41, 51] and contamination of intravenous catheter insertion sites [40] . In our review, catheter tip culture results were positive in 6 cases (9.8%).
Hospital-acquired transmission has been demonstrated [3, 36, 45, 59] , and both transmission from the environment and person-to-person transmission are possible [45, 52, 60] . S. cerevisiae fungemia may also be a self-inflicted disease [13, 28] . Finally, the difference in virulence between clinical and nonclinical strains may explain different degrees of invasiveness [1, 61, 62] The most consistent risk factor for S. cerevisiae fungemia is the use of probiotics. Despite the fact that, in many cases, the use of Ultralevura was not specified, 26 cases of S. cerevisiae fungemia-including ours-have been directly related to the oral administration of Ultralevura [15, 16, 18, 24, 25, 27, 30, 31, 34-37, 40, 45, 46 ] . In another 5 cases, the fungemic patients were reported to have been in the vicinity of probiotic-treated patients [3, 36, 45] . Fungemia was detected a median of 10 days after the administration of the probiotic (range, 4-300 days).
The use of probiotics may be especially dangerous in patients at high risk for infection. In fact, 15 of the 26 patients who developed fungemia after receipt of probiotic therapy were reported to be in the ICU, were receiving enteral feeding, had a central venous catheter in place, and were receiving antimicrobials. In these ICUs, at least 2 outbreaks (besides ours) have been described [3, 45] . It has been demonstrated that, when the probiotic capsules are opened for administration through the nasogastric tube, viable yeasts may be detected at a 1-m distance as a result of aerial transmission, and the yeasts persist on room surfaces after 2 h. They can be detected on the bare hands of health care workers even after vigorous hand washing [40] . In this setting, central venous catheters may be easily contaminated and become the portal of entry [40] . S. cerevisiae was recovered from the catheter hub of 1 of our patients, and catheter-related fungemia was further demonstrated by means of lysis centrifugation blood cultures.
As previously mentioned, classic severe immunosuppression is not a prerequisite for developing S. cerevisiae fungemia. In our review, 35 (71%) of the 49 patients with fungemia were receiving enteral or parenteral nutrition, 55 (93%) of 59 had a central venous catheter in place, and 44 (88%) of 50 had received broad-spectrum antimicrobials.
S. cerevisiae can cause a wide variety of clinical syndromes, such as pneumonia [19, 54] , empyema [56] , liver abscess [19] , peritonitis [53, 63, 64] , vaginitis [65] [66] [67] [68] , esophagitis [54, 69, 70] , urinary tract infection [55, 71] , cellulitis [72] , unexplained fever, or septic shock [56] . S. cerevisiae has also been associated with Crohn disease, and the presence of antibodies against this microorganism is considered to be a sensitive (50%) and specific (90%) diagnostic test [73] [74] [75] [76] . The microorganism has also been described in patients with asthma [77] , ulcerative colitis, and diarrhea [78] .
However, the most important clinical syndrome caused by S. cerevisiae is fungemia, because it is usually the most severe and well-proven clinical manifestation of the disease. S. cerevisiae fungemia has been described in immunosuppressed patients (19 patients [31%] ) and critically ill patients (28 [46%] ), but also in relatively healthy hosts. Underlying conditions include cancer [17, 19] , HIV infection [16, 40, 46] , use of corticosteroids [31, 78] , neutropenia [19, 20, 29, 35] , bone marrow transplantation [22, 27, 52] , solid organ transplantation [46] , burns [14, 25] , and heart surgery [10, 26, 35, 38, [43] [44] [45] . Critically ill neonates seem to be particularly predisposed to fungemia [20, 32, 33, 35, 36, 42, 43, 47] .
Five patients with S. cerevisiae fungemia were found to have infectious endocarditis (including our case) [10, 26, 38, 39, 43] . Two of the 5 patients died. We have also identified a patient with infection of an aortic-bifemoral graft who developed aorto-enteric fistula and finally died of the infection [44] .
Therapy for S. cerevisiae fungemia should rely on the withdrawal of the probiotic preparation, if it was being given, administration of an antifungal agent, and, as with other types of fungemia, withdrawal of central venous catheters [45, 48] . Persistent fungemia in patients with incomplete removal of prosthetic materials has been reported [32, 48] .
The antifungal agent of choice has not been established. S. cerevisiae has been consistently susceptible to amphotericin B (MIC 90 , 0.5-1 mg/mL) and fluorocytosine (MIC 90 , 0.25 mg/mL), whereas different rates of resistance to fluconazole and itraconazole have been reported [41, 52, 79, 80] . The isolates exhibited in vitro resistance to itraconazole (MIC, 1-16 mg/mL), and the MIC 90 to fluconazole was 8-128 mg/mL. We tested our 4 isolates and found that the most potent antifungal compounds in vitro were flucytosine and voriconazole, with MICs of р0.25 mg/mL. Besides, no therapeutic failure has been clearly attributable to resistance, even in strains with reduced susceptibility to fluconazole (MIC, 32 mg/mL) [40] , although cases of fungemia occurred in patients receiving fluconazole or ketoconazole [29, 35] .
Until more data are available, the antifungal agent of choice seems to be amphotericin B. However, this does not imply, in our opinion, the impossibility of treating patients with fluconazole, because most MICs obtained for this drug are within the susceptibility range, and many successful results obtained with fluconazole have been reported in the literature (table 1) . Despite the fact that data are scarce, both posaconazole and voriconazole have been reported to have good in vitro activity against this fungus [81] [82] [83] [84] [85] .
The mortality rate for patients with S. cerevisiae fungemia was 29.5% (18 patients), although, in most cases, mortality could not be only attributed to fungemia. However, septic shock has been reported in patients with S. cerevisiae fungemia as a single isolate [36, 40] , and Piarroux et al. [48] described a patient who died of sepsis even though Saccharomyces was the only microorganism isolated from blood cultures.
S. cerevisiae should not be dismissed as a nonpathogenic microorganism when recovered from a clinical source. A history of intake of health food supplements or probiotics should be investigated.
